The Diabetes Care segment is the core focus of Tonghua Dongbao, encompassing the research, development, manufacturing, and commercialization of insulin analogs, oral hypoglycemic drugs, and related medical devices. R&D activities include the development of new insulin formulations, biosimilars, and combination therapies. Technologies employed involve advanced protein engineering, formulation science, and analytical methods for drug characterization. This segment addresses the global need for effective diabetes management, improving patient outcomes by providing accessible and affordable treatment options. Market positioning is strong in China, with a growing presence internationally. Future opportunities include expansion into new markets, development of next-generation insulin products, and strategic partnerships to enhance product offerings. Regulatory and clinical aspects involve rigorous clinical trials and adherence to global standards for drug approval. Partnerships with companies like Adocia facilitate the development of innovative insulin delivery systems.

This segment focuses on the development and commercialization of drugs for cardiovascular diseases. Research and development efforts are directed towards identifying and developing novel therapies for conditions such as hypertension, hyperlipidemia, and heart failure. Technologies used include drug discovery platforms, formulation science, and clinical trial management. The segment aims to improve patient outcomes by providing effective treatments to reduce the incidence of cardiovascular events and improve overall health. Market positioning is focused on the Chinese market, with potential for expansion into other regions. Future opportunities include the development of new drug candidates, strategic partnerships, and expansion of the product portfolio. Regulatory and clinical aspects involve conducting clinical trials and obtaining regulatory approvals. This segment is crucial for addressing the growing prevalence of cardiovascular diseases.